Rigel Pharmaceuticals (RIGL) Free Cash Flow Growth (1y) (2011 - 2026)
Rigel Pharmaceuticals (RIGL) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,921.77 Bn | 66,921.49 Bn | - | 7.12% |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.57 Bn | 466.77 Bn | 1.35 Bn | 1,092.51% |
| 5 | Vertex Pharmaceuticals | 122.01 Bn | 114.76 Bn | 2.59 Bn | 66.37% |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn | 3.98% |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | 137.65% |
| 10 | Rigel Pharmaceuticals | 705.69 Mn | 559.00 Mn | 54.21 Mn | 405.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 405.15% |
| Dec 31, 2025 | 51.55% |
| Sep 30, 2025 | 10.85% |
| Jun 30, 2025 | 10,011.59% |
| Mar 31, 2025 | 82.19% |
| Dec 31, 2024 | 331.34% |
| Sep 30, 2024 | 1,678.95% |
| Jun 30, 2024 | -94.91% |
| Mar 31, 2024 | -26.08% |
| Dec 31, 2023 | 72.56% |
| Sep 30, 2023 | 89.12% |
| Jun 30, 2023 | 146.07% |
| Mar 31, 2023 | 84.63% |
| Dec 31, 2022 | -22.92% |
| Sep 30, 2022 | -20.60% |
| Jun 30, 2022 | -123.52% |
| Mar 31, 2022 | -29.64% |
| Dec 31, 2021 | -11.24% |
| Sep 30, 2021 | 46.73% |
| Jun 30, 2021 | 508.81% |